In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance vs. placebo at 52 weeks following weight loss on Wegovy or Zepbound
Participants who swit… [+29446 chars]
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Source:Lilly.com
Published:
Related News
Yen Rises as Warning From Takaichi Raises Intervention Risk - Bloomberg
The yen extended gains to as much as 1.2% against the dollar as traders are on heightened alert for authorities intervening in the market following its recent slide.
Bloomberg•John Cheng
Japan Government Bond Yields, Stocks Fall After Yen’s Rebound - The Wall Street Journal
The Wall Street Journal•The Wall Street Journal
Samsung Stock Gains as Nvidia AI Chip Supply Nears - TipRanks
South Korean market leader Samsung Electronics ($SSNLF) is set to begin production of its next-generation high-bandwidth memory chips, known as HBM4, as early as next month, according to a Reuters
Tipranks.com•Shalu Saraf